biotech private markets

Institutional portfolio allocation in life sciences is undergoing a structural shift as capital flows increasingly target innovation-driven healthcare segments. Large asset managers, pension funds, and sovereign wealth funds are refining allocation strategies to balance high-growth biotech opportunities with regulatory and clinical risk exposure. This trend reflects a broader recognition that life sciences is not only … Read more